Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allegra-6 grass pollen sublingual immunotherapy study
2007-000823-16Phase 3Completed
- Sponsor
- Allergopharma
- Start
- Jun 2007
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Oralair in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and grass pollen allergy (2 arms), sponsored by Allergopharma. Primary endpoint: Change in Area Under the Curve of Symptom-Medication Score. Started Jun 2007; status: completed.
02
Drugs
Oralair
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)grass pollen allergy
Beyond the preview
Go deeper on 2007-000823-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000823-16.